EDWARD B. LEAHEY JR., M.D.; J. THOMAS BIGGER JR., M.D.
This content is PDF only. Please click on the PDF icon to access.
The treatment of ventricular arrhythmias remains a major challenge. Ventricular arrhythmias may be symptomatic; ventricular arrhythmias after myocardial infarction have recently been correlated with subsequent mortality (1-3). An unproven hypothesis is that suppression of the arrhythmia will prevent these deaths. Both treatment of symptomatic arrhythmias and the possible prevention of sudden death provide impetus to search for better antiarrhythmic drugs. An ideal antiarrhythmic drug would be highly effective, would have a low incidence of toxicity, would have a large therapeutic to toxic effects ratio, and would allow once a day dosing. Unfortunately, no such ideal drug is currently available. Because
LEAHEY EB, BIGGER JT. Mexiletine: A New Antiarrhythmic Drug. Ann Intern Med. ;92:427–429. doi: 10.7326/0003-4819-92-3-427
Download citation file:
Published: Ann Intern Med. 1980;92(3):427-429.
Cardiology, Rhythm Disorders and Devices.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use